WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare Conference ...

In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), ...

RBC Capital Mkts has recently initiated Apellis Pharmaceuticals Inc (APLS) stock to Sector Perform rating, as announced on October 25, 2024, according to Finviz. Earlier, on October 16, 2024, William ...

This page features the latest news about the Apellis Pharma share. Citi reiterates Apellis stock as a 'BUY' on transformative pegcetacoplan data On Monday, Citi reaffirmed its Buy rating on Apellis ...

Featured here, the Balance Sheet for Apellis Pharmaceuticals Inc, which summarizes the company's financial position including assets, liabilities and shareholder equity for each of the latest 10 ...

On Monday, Citi reaffirmed its Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) stock with a steady price target of $63.00. The endorsement follows the company's presentation at the American ...

On Monday, Citi reaffirmed its Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) stock with a steady price target of $63.00. The endorsement follows the company's presentation at the American ...

https://www.tipranks.com/news/company-announcements/kiora-pharmaceuticals-gains-approval-for-phase-2-trial Apellis (APLS) Pharmaceuticals and Sobi announced that ...